Dual PD-1 and CTLA-4 Checkpoint Blockade Promotes Antitumor Immune Responses through CD4+ Foxp3- Cell-Mediated Modulation of CD103+ Dendritic Cells

Cancer Immunology Research
Paul A BeavisPhillip K Darcy

Abstract

Immunotherapy is widely accepted as a powerful new treatment modality for the treatment of cancer. The most successful form of immunotherapy to date has been the blockade of the immune checkpoints PD-1 and CTLA-4. Combining inhibitors of both PD-1 and CTLA-4 increases the proportion of patients who respond to immunotherapy. However, most patients still do not respond to checkpoint inhibitors, and prognostic biomarkers are currently lacking. Therefore, a better understanding of the mechanism by which these checkpoint inhibitors enhance antitumor immune responses is required to more accurately predict which patients are likely to respond and further enhance this treatment modality. Our current study of two mouse tumor models revealed that CD4+Foxp3- cells activated by dual PD-1/CTLA-4 blockade modulated the myeloid compartment, including activation of conventional CD103+ dendritic cells (DC) and expansion of a myeloid subset that produces TNFα and iNOS (TIP-DCs). CD4+Foxp3- T cell-mediated activation of CD103+ DCs resulted in enhanced IL12 production by these cells and IL12 enhanced the therapeutic effect of dual PD-1/CTLA-4 blockade. Given the importance of these myeloid subsets in the antitumor immune response, our data point t...Continue Reading

References

Jul 7, 1997·The Journal of Experimental Medicine·S R BennettW R Heath
Mar 10, 2001·The Journal of Immunology : Official Journal of the American Association of Immunologists·T F GajewskiM L Alegre
Aug 22, 2007·The Journal of Immunology : Official Journal of the American Association of Immunologists·Trina J Stewart, Scott I Abrams
Mar 26, 2008·The Journal of Experimental Medicine·Mirjam KoolBart N Lambrecht
Nov 26, 2008·The Journal of Experimental Medicine·Susan GilfillanMarco Colonna
Feb 18, 2010·Proceedings of the National Academy of Sciences of the United States of America·Michael A CurranJames P Allison
Oct 15, 2011·Nature Reviews. Immunology·Peter J Murray, Thomas A Wynn
Mar 23, 2012·Nature Reviews. Cancer·Drew M Pardoll
Jun 5, 2012·The New England Journal of Medicine·Julie R BrahmerJon M Wigginton
Sep 11, 2013·The Journal of Immunology : Official Journal of the American Association of Immunologists·Sandro PratoJose A Villadangos
Apr 10, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Janis M TaubeRobert A Anders
Apr 30, 2014·Cancer Immunology Research·Derek Ng TangPadmanee Sharma
Nov 28, 2014·Nature·Matthew M GubinRobert D Schreiber
Dec 30, 2014·The Journal of Immunology : Official Journal of the American Association of Immunologists·Rituparna DasKavita M Dhodapkar
Feb 11, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Dirk SchadendorfJedd D Wolchok
Mar 11, 2015·Nature·Christina Twyman-Saint VictorAndy J Minn
Apr 23, 2015·Nature·Sebastian KreiterUgur Sahin
Aug 25, 2015·BMC Medicine·Sathana DushyanthenSherene Loi
Nov 13, 2015·American Journal of Clinical Oncology·Elizabeth I Buchbinder, Anupam Desai
Jan 21, 2016·Cancer Immunology Research·Antoni RibasBegoña Comin-Anduix
May 5, 2016·Nature Reviews. Clinical Oncology·Celine BoutrosCaroline Robert
Jun 25, 2016·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Matteo S Carlino, Georgina V Long
Jun 29, 2016·Nature·Els M E VerdegaalSjoerd H van der Burg
Nov 3, 2016·Cancer Research·Shin Foong NgiowMark J Smyth

❮ Previous
Next ❯

Citations

Mar 15, 2020·Journal of Leukocyte Biology·Spencer E BrightmanStephen P Schoenberger
Feb 28, 2019·Frontiers in Immunology·Jean-Charles CancelRaphaël Mattiuz
Sep 16, 2020·Nature Reviews. Drug Discovery·Simon J HoggRicky W Johnstone
Jul 28, 2020·Cells·Francesca SillitoHans J Stauss
Aug 28, 2020·Frontiers in Immunology·Shin Foong Ngiow, Arabella Young
Nov 27, 2019·Clinical & Translational Immunology·Amanda J OliverClare Y Slaney
Oct 23, 2019·Proceedings of the National Academy of Sciences of the United States of America·Spencer C WeiJames P Allison
Nov 4, 2020·Cancer Immunology, Immunotherapy : CII·Anne ScheuerpflugRalph Mocikat
Nov 27, 2020·Journal for Immunotherapy of Cancer·Nahee ParkYong Wha Moon
Oct 23, 2019·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Imran G HousePaul A Beavis
Feb 16, 2021·Current Opinion in Immunology·Vikas Duhan, Mark J Smyth
Feb 20, 2021·Journal of Experimental & Clinical Cancer Research : CR·Allan RelecomSaid Dermime
Dec 24, 2020·Cancer Immunology Research·Brian B HainesChristophe Quéva
Mar 30, 2021·Frontiers in Immunology·Jongdae LeeJose M González-Navajas
May 4, 2021·Frontiers in Endocrinology·Sergio Di MolfettaAntongiulio Faggiano
Mar 12, 2021·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Yong LiangYang-Xin Fu
Nov 17, 2021·Cancer Immunology Research·Lisa C WellingerRicky W Johnstone

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Vaccines

Cancer vaccines are vaccines that either treat existing cancer or prevent development of a cancer.

Cell Checkpoints & Regulators

Cell cycle checkpoints are a series of complex checkpoint mechanisms that detect DNA abnormalities and ensure that DNA replication and repair are complete before cell division. They are primarily regulated by cyclins, cyclin-dependent kinases, and the anaphase-promoting complex/cyclosome. Here is the latest research.